Shuttle Pharmaceuticals Holdings, Inc. Logo

Shuttle Pharmaceuticals Holdings, Inc.

Develops drugs to enhance radiation therapy for cancer and offers predictive diagnostics.

SHPH | US

Overview

Corporate Details

ISIN(s):
US8256933024
LEI:
Country:
United States of America
Address:
401 PROFESSIONAL DRIVE, 20879 GAITHERSBURG
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to improving outcomes for cancer patients by enhancing the effectiveness of radiation therapy (RT). The company develops novel therapies designed to sensitize cancer cells to radiation while protecting healthy tissues. Its lead product candidate, Ropidoxuridine, is a Phase II clinical-stage oral radiation sensitizer. The development pipeline also includes a portfolio of pre-clinical selective histone deacetylase (HDAC) inhibitors. In addition to therapeutics, Shuttle Pharma is developing diagnostic technologies, such as predictive blood tests for prostate cancer patients, to inform therapeutic decision-making and patient management. The company utilizes a proprietary drug discovery platform and strategic collaborations to advance its mission of increasing cancer cure rates and improving patient quality of life.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Shuttle Pharmaceuticals Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shuttle Pharmaceuticals Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Shuttle Pharmaceuticals Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY
New Nordic Healthbrands AB Logo
Develops and markets herbal supplements & beauty products for natural wellness consumers globally.
Sweden
NNH
Newron Pharmaceuticals S.p.A. Logo
Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.
Italy
NWRN
NEXGEL, INC. Logo
Develops and manufactures advanced hydrogels for healthcare, OTC, and consumer applications.
United States of America
NXGL
NextCell Pharma AB Logo
Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.
Sweden
NXTCL
NextCure, Inc. Logo
Clinical-stage biopharma developing novel immunomedicines for cancer and other diseases.
United States of America
NXTC
NGeneBio Co., Ltd. Logo
Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.
South Korea
354200
NIBEC CO., LTD. Logo
Biotech CDMO creating regenerative products with peptide and biomaterial technologies.
South Korea
138610
NIPPON CHEMIPHAR CO., LTD. Logo
Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.
Japan
4539
Nippon Shinyaku Co.,Ltd. Logo
Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.
Japan
4516

Talk to a Data Expert

Have a question? We'll get back to you promptly.